IBI-3002

N/A

Report date: 2026/03/04 20:01:44

First In Class

Base Information

Drug NameIBI-3002

Drug Alias NameIBI3002IBI-3002

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionInterleukin-4 receptor subunit alpha inhibitorsThymic stromal lymphopoietin inhibitors

TargetsInterleukin-4 receptor subunit alphaThymic stromal lymphopoietin

Therapy Area/IndicationsDermatitis, AtopicAsthma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustraliaMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesInnovent Biologics(Suzhou) Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesInnovent Biologics(Suzhou) Co Ltd

Inactive CompaniesN/A

Active IndicationsDermatitis, AtopicAsthma

Inactive IndicationsN/A

Other Information

ATC CodeN/A